An exciting new initiative called ‘Patents 4 Patients’ was recently launched in the United States (US). The initiative aims to halve the time it takes to examine patent applications at the US Patent and Trademark Office (USPTO) for cancer immunotherapy.
The initiative is equally available to early stage biotech companies, universities and large pharma businesses.
This should mean patients start receiving new cancer treatments considerably quicker as the red tape to obtaining patents on these drugs is being substantially reduced. The aim is for final examination decisions on cancer immunotherapy patents to take less than 12 months.